Table 2. Efficacy results based on IRC assessment in the ITT population (n=56).

Outcome	Value
Best tumour response, n (%)
Complete response	1 (2)
Partial response	16 (29)
Stable disease	27 (48)
Progressive disease	5 (9)
Not evaluable	7 (13)
Overall best response rate (95% CI)	30.4 (19.0–44.0)
Median duration of response (95% CI, months)	7.69 (5.95–9.46)
Median time to progression (95% CI, months)	5.45 (3.02–7.52)
Median survival time (95% CI, months)	14.85 (11.73–17.97)

CI=confidence interval; IRC=independent review committee; ITT=intent-to-treat.